Showing 7931-7940 of 10548 results for "".
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- Online Team-Based Care Matches In-Person Outcomes for Atopic Dermatitis: Analysishttps://practicaldermatology.com/news/online-team-based-care-matches-in-person-outcomes-for-atopic-dermatitis-analysis/2487582/A team-based connected health (TCH) model delivered online achieved equivalent improvements in atopic dermatitis (AD) severity compared with traditional in-person care, according to results from a randomized clinical trial. T
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Paroxetine Linked to Neurovascular and Immune Proteomic Changes in Refractory Rosacea: Analysishttps://practicaldermatology.com/news/paroxetine-linked-to-neurovascular-and-immune-proteomic-changes-in-refractory-rosacea/2487517/A secondary analysis of a randomized clinical trial in JAMA Dermatology identified systemic proteomic changes associated with paroxetine treatment in patients with refractory erythematous rosacea, offering new insight into
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Review: Emerging Therapies Expand Options for Patients With Genodermatoseshttps://practicaldermatology.com/news/review-emerging-therapies-expand-options-for-patients-with-genodermatoses/2487464/A new review published in the Journal of Drugs in Dermatology spotlighted recent advances in the diagnosis, classification, and treatment of several common genodermatoses, incl
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- BE BOLD at 16 Weeks: Bimekizumab Outperforms Risankizumab for PsAhttps://practicaldermatology.com/news/bimekizumab-outperforms-risankizumab-for-psa/2487356/New data from the Phase 3 BE BOLD study show that bimekizumab (Bimzelx; UCB) achieved superior joint responses compared with risankizumab (Skyriz
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob